Samanta Cimitan appointed as CEO of the Celonic Group

Thursday, August 3, 2023 @ 9:00 am

Celonic Group, a Swiss-based Biologics Contract Development and Manufacturing Organization (CDMO), has appointed Dr. Samanta Cimitan as the Chief Executive Officer (CEO) of the Celonic Group, a subsidiary of the independent and privately owned J.RETTENMAIER & Söhne Company (JRS Group).

Samanta succeeds Dr. Konstantin Matentzoglu, who will step down after 9 years as CEO. During his tenure, Konstantin successfully repositioned the Celonic brand as a premium CDMO, delivered significant growth, and facilitated corporate development and strategic alliances. Konstantin Matentzoglu intends to remain a Member of the Celonic Board and will support Samanta during the transition.

With more than 20 years of experience working, teaching, and studying Life Sciences, Samanta is an expert in the CDMO industry, holding a deep and unique combination of scientific, commercial, and operational know-how.

Samanta joined Celonic in June 2022 as Chief Business Officer (CBO). During this time, she quickly articulated a new strategic direction for the Celonic business, solidified customer relationships, and accelerated innovation.

Prior to Celonic, Samanta was with Lonza for almost 13 years, holding several leadership positions across multiple commercial and strategy roles, including Vice President of Lonza Group Operations Strategy, developing and leading transformational programs across R&D, Operations and Commercial functions. Samanta holds a Ph.D. in Pharmaceutical Sciences from the University of Bologna, Italy, along with a master’s degree in Industrial Chemistry.

Josef Otto Rettenmaier, Chairman of the JRS Group: “I am excited to welcome Samanta to the role of Chief Executive Officer (CEO). She is a respected leader with an impressive track record. Her appointment will further solidify Celonic’s commitment to be a quality, world-class Biologics CDMO bringing life-saving drugs to the market. With her expertise, Samanta will help drive accelerated growth and long-term success for Celonic at this pivotal time.”

Dr. Samanta Cimitan says: “It is an honor to be appointed CEO of the Celonic Group. I am energized to leverage the talent, expertise and passion of the entire Celonic organization to meet and exceed our customer expectations and bring game-changing technologies to the market”.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Ymmunobio honored with 3rd place at the Prix Galien USA Awards

Ymmunobio is proud to announce its recent recognition at the prestigious Prix Galien USA Awards, where the company achieved a 3rd-place honor. The Prix Galien Award acknowledges Ymmunobio’s dedication to advancing science and healthcare.
November 15, 2024

Pharvaris: 3rd quarter 2024 financial results and business updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the
November 13, 2024

Aurealis Therapeutics: CHF 8M for chronic wounds studies and oncology program

Funds will be used to complete Phase 2 RCTs with AUP-16 for Chronic Wounds, and accelerate the development of AUP-55 for ovarian, peritoneal and bladder cancer.
November 13, 2024

Nouscom’s neoantigen immunotherapy with potential to ‘intercept’ cancer in Lynch Syndrome carriers

Lynch Syndrome (LS) is a common hereditary condition (affecting one in 300) conferring a high risk of developing colorectal, gastric, endometrial and other cancers NOUS-209 monotherapy is well tolerated and generates potent and long-lasting neoantigen-specific T cell responses Updated data to be presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
November 5, 2024

InSphero partners with Chayon in South Korea for in vitro technologies

InSphero, the pioneer in 3D cell culture and organ-on-chip technologies, today announced its distribution partnership with Chayon, a leading Seoul-based laboratory supplies provider. This partnership will bring InSphero’s reliable and scalable 3D in vitro solutions for drug development to South Korean researchers, further expanding the company’s global footprint.
November 4, 2024